Form 10-Q NEKTAR THERAPEUTICS For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Tesla acquires AI hardware company for up to $2 billion in stock
Nektar Therapeutics (NKTR) PT Raised to $20 at Oppenheimer
November 7, 2019 10:24 AM ESTOppenheimer analyst Jay Olson raised the price target on Nektar Therapeutics (NASDAQ: NKTR) to $20.00 (from $18.00) while maintaining a Perform rating.
The analyst commented, "Nektar reported 3Q19 financial results, revised 2019 guidance, and provided pipeline updates including multiple catalysts. While NKTR has several promising... More
